EBV-associated cutaneous plasmocytoma in a renal transplant patient;Plasmocytome cutané EBV+ isolé chez une malade transplantée rénale: Efficacité d'un traitement par rituximab

Annales de Dermatologie et de Venereologie

Volumn 131, Issue 12, 2004, Pages 1081-1084

  Carbonnelle, A ^a   Mahe E ^a   Morelon, E ^a   Varet, B ^a   Kreis, H ^a   Brousse, N ^a   Fraitag, S ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE 3 SULFOBENZOATE; RITUXIMAB; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PLASMACYTOMA; POLYMERASE CHAIN REACTION; REMISSION; SKIN BIOPSY; SKIN MANIFESTATION; SUBCUTANEOUS NODULE; TREATMENT OUTCOME; VIRUS DETECTION;

EID: 11244329175     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(04)93845-8     Document Type: Article

References (22)

1. Berg LC, Copenhayer CM, Morrison VA, Gruber SA, Dunn DL, Gajl-Peczalska K et al. B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization. Hum Pathol 1992;23:159-63.
2. Blokx WA, Andriessen MP, van Hamersvelt HW, van Krieken JH. Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the literature on cutaneous B-cell posttransplantation lymphoproliferative disease. Am J Dermatopathol 2002; 24:414-22.
3. Schumann KW, Oriba HA, Bergfeld WF, Hsi ED, Hollandsworth K. Cutaneous presentation of posttransplant lymphoproliferative disorder. J Am Acad Dermatol 2000;42:923-6.
4. McGregor JM, Yu CC, Lu QL, Cotter FE, Levison DA, MacDonald DM. Posttransplant cutaneous lymphoma. J Am Acad Dermatol 1993;29:549-54.
5. Chai C, White WL, Shea CR, Prieto VG. Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin. J Cutan Pathol 1999;26:242-7.
6. Gonthier DM, Hartman G, Holley JL. Posttransplant lymphoproliferative disorder presenting as an isolated skin lesion. Am J Kidney Dis 1992; 19:600-3.
7. Fischer T, Miller M, Bott-Silverman C, Lichtin A. Posttransplant lymphoproliferative disease after cardiac transplantation. Two unusual variants with predominantly plasmacytoid features. Transplantation 1996; 62:1687-90.
8. Chucrallah AE, Crow MK, Rice LE, Rajagopalan S, Hudnall SD. Multiple myeloma after cardiac transplantation: an unusual form of posttransplant lymphoproliferative disorder. Hum Pathol 1994;25:541-5.
9. Howard AD, Moore J Jr, Tomaszewski MM. Occurrence of multiple myeloma three years after successful renal transplantation. Am J Kidney Dis 1987;10:147-50.
10. Melato M, Paladini G. Multiple myeloma following reactivated Epstein-Barr virus infection in a renal-transplant recipient. Haematologica 1986;71:241-3.
11. Leigh BR, Larkin EC, Doggett RL. Solitary extramedullary plasmocytoma five years after successful cardiac transplantation: case report and review of the literature. Am J Clin Oncol 1997;20:467-70.
12. Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995;147:1862-70.
13. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-27.
14. Hsieh WS, Lemas MV, Ambinder RF. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. Transpl Infect Dis 1999;1:204-12.
15. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8-14.
16. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM. Bcl-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998;92:2294-302.
17. Chadburn A, Cesarman E, Knowles DM. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997;14:15-26.
18. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
19. Ferry JA, Jacobson JO, Conti D, Delmonico F, Harris NL. Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 1989;2:583-92.
20. Randhawa PS, Magnone M, Jordan M, Shapiro R, Demetris AJ, Nalesnik M. Renal allograft involvement by Epstein-Barr virus associated post-transplantlymphoproliferative disease. Am J Surg Pathol 1996;20:563-71.
21. Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989;47:293-6.
22. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. Nephrol Dial Transplant 2002; 17(Suppl 4):1-67.